<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
  <meta name="title" content="Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC : AZD7442 PhIII trial positive in COVID â€¦"/>
  <meta name="description" content="AstraZeneca&#39;s new antibody has been given a significant reduction in the risk of developing severe Covid-19 or death in patients with mild-to-moderate symptomatic COVID-19 - according to the British Medical Journal (BMJ) ."/><meta name="robots" content="index,follow"/><link rel="canonical" href="https://datosabiertos.com/open_data/2021-10-11/investegate-astrazeneca-plc-announcements-astrazeneca-plc-azd7442-phiii-trial-positive-in-covid-outpatients/">
  <link rel="icon" href="/img/favicon.ico"/>

  <title>Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC : AZD7442 PhIII trial positive in COVID outpatients - Open Data</title>

  <link rel="preload" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
  <noscript><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css" integrity="sha384-xOolHFLEh07PJGoPkLv1IbcEPTNtaed2xpHsD9ESMhqIYd0nLMwNLD69Npy4HI+N" crossorigin="anonymous"></noscript>

  
  <link rel="stylesheet" href="/css/custom.css">
</head>

<body>
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MXMNS5J"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
  <main role="main" class="container">
    
    <header class="site-header py-3">
      <div class="row flex-nowrap justify-content-between align-items-center">
        <div class="col pt-1">
          <a class="site-header-name" href="/">
            <h1 class="site-header-name">Open Data</h1>
          </a>
        </div>
      </div>
    </header>
    

    
    <div class="container nav-bar">
      <div class="row nav">
        <a class="col-md-auto p-2" href="/es/">ES</a>
        <a class="col-md-auto p-2" href="/">EN</a>
      </div>
    </div>
    

    <div class="row">

      
      <div class="col">
        
<div class="content is-medium">
  <p class="article_item">
    <a href="https://www.investegate.co.uk/astrazeneca-plc--azn-/rns/azd7442-phiii-trial-positive-in-covid-outpatients/202110110700105779O/" target="_new">Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC : AZD7442 PhIII trial positive in COVID outpatients</a>
    <p>AstraZeneca&#39;s new antibody has been given a significant reduction in the risk of developing severe Covid-19 or death in patients with mild-to-moderate symptomatic COVID-19 - according to the British Medical Journal (BMJ) .</p>
    <b style="font-weight: bold;">Source: <i>investegate.co.uk</i></b>
    <br/>Published on <a href="/open_data/2021-10-11/">2021-10-11</a>
  </p>
</div>

    <div class="content is-medium">
        <h3>Related news</h3>
        <ul>
        
            <li><a href="/open_data/2021-10-11/azd7442-reduced-risk-of-developing-severe-covid-19-or-death-in-tackle-phase-iii-outpatient-treatment-trial">AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial</a></li>
        
            <li><a href="/open_data/2021-12-23/2021-12-23--evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities">EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities</a></li>
        
            <li><a href="/open_data/2021-10-12/astrazeneca-plc-via-public-azd7442-reduced-risk-of-developing-severe-covid-19-or-death-in-tackle-phase-iii-outpatient-treatment-trial">AstraZeneca plc ( via Public ) / AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial</a></li>
        
            <li><a href="/open_data/2022-01-11/2022-01-11--safety-and-immunogenicity-of-2-dose-heterologous-ad26-zebov-mva-bn-filo-ebola-vaccination-in-children-and-adolescents-in-africa-a-randomised-placebo-c">Safety and immunogenicity of 2 - dose heterologous Ad26 . ZEBOV , MVA - BN - Filo Ebola vaccination in children and adolescents in Africa : A randomised , placebo - controlled , multicentre Phase II clinical trial</a></li>
        
            <li><a href="/open_data/2021-11-18/2021-11-18--new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention">New Analyses of Two AZD7442 COVID - 19 Phase III Trials in High - Risk Populations Confirm Robust Efficacy and Long - Term Prevention</a></li>
        
            <li><a href="/open_data/2022-09-12/2022-09-12--continued-attendance-in-a-prep-program-despite-low-adherence-and-non-protective-drug-levels-among-adolescent-girls-and-young-women-in-kenya-results-fr">Continued attendance in a PrEP program despite low adherence and non - protective drug levels among adolescent girls and young women in Kenya : Results from a prospective cohort study</a></li>
        
            <li><a href="/open_data/2021-12-21/2021-12-21--evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study">Evusheld long - acting antibody combination retains neutralising activity against Omicron variant in independent FDA study</a></li>
        
            <li><a href="/open_data/2021-12-25/2021-12-25--evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities">EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities</a></li>
        
        </ul>
    </div>
<div class="row">
  <div class="col-md-6">
    
      <a href="/open_data/2021-10-11/lf-edge-welcomes-new-premier-members-f5-vmware-as-it-matures-into-a-framework-for-real-world-edge-telco-and-iot-solutions/">&laquo;&nbsp;LF Edge Welcomes New Premier Members F5 , VMware as it matures into a Framework for Real - World Edge , Telco , and IoT Solutions</a>
    
  </div>
  <div class="col-md-6 text-right">
    
      <a href="/open_data/2021-10-11/huawei-presents-fusionsolar-all-scenario-smart-pv-storage-solution-at-intersolar-2021/">Huawei presents FusionSolar All - Scenario Smart PV &amp; Storage Solution at Intersolar 2021 &nbsp;&raquo;</a>
    
  </div>
</div>

    </div>
  </main>

  <footer class="site-footer">

    <div class="row">
      <div class="col-md-3"></div>
      <div class="col-md-3 col-md-center">

      </div>
      <div class="col-md-3 col-md-center">

      </div>
    </div>
  </div>
  </footer>

  
  

  
  
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
            new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
            j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
            '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
            })(window,document,'script','dataLayer','GTM-MXMNS5J');
        </script>
    

  
  <script src="https://cdn.jsdelivr.net/npm/jquery@3.5.1/dist/jquery.slim.min.js" integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-Fy6S3B9q64WdZWQUiU+q4/2Lc9npb8tCaSX9FK7E8HnRr0Jz8D6OP9dO5Vg3Q9ct" crossorigin="anonymous"></script>

</body>

</html>
